Indian Pharmaceutical Alliance’s Post

"On both sides of the Atlantic, generic and biosimilar medicines play a critical role in enhancing patient access and healthcare sustainability, accounting for 70% of medicines prescribed in the EU and 90% of prescriptions filled in the US. Almost 77% of all prescriptions dispensed in Canada in 2023 were for generic medicines..." Industry experts with the Association for Accessible Medicines, Canadian Generic Pharmaceutical Association and Medicines for Europe have announced a new transatlantic partnership for the secure supply of medicines --- focusing on three essential areas of collaboration: 💊 Security of medicines supply  ⛑ Solidarity-based responses to crises 🌎 Bilateral and multilateral regulatory cooperation READ the full publication: https://lnkd.in/e459KH_a Biosimilars Council #generics #biosimilars #rx

Recently, the Brazilian Health Regulatory Agency (ANVISA) took a significant step by approving RDC No. 875 on May 28, 2024. This new regulation establishes for the registration of biosimilars in Brazil, marking an important milestone for the pharmaceutical industry. Biosimilars represent a viable alternative to original biological drugs, potentially reducing treatment costs for various diseases. With this regulation, ANVISA aims to ensure that these products meet the highest standards of quality, safety, and efficacy, benefiting patients and healthcare professionals. Discover the insightful content created by Viviane Yumy Kunisawa, Ph.D., a Partner at Daniel.

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) are diligently working to incorporate data analysis into their assessment processes, significantly enhancing decision-making capabilities. Their comprehensive Big Data workplan, spanning from 2022 to 2025, is already underway, with the DFQ (Data Quality Framework) serving as the first and foundational framework emphasizing: ➡️ Theoretical definition of data quality dimensions. ➡️ Standardized approach to assessing data quality and representativeness ➡️ Establishment of a foundation for developing implementable guidelines Read here my article to know more about the framework: https://lnkd.in/ev9dYJ63

🔗 Ziva DRA: Your Trusted Partner for API Registration in Bangladesh! 🔗 Ziva DRA now offers specialized Active Pharmaceutical Ingredients (API) registration services tailored for Bangladesh. With our deep expertise and streamlined processes, we ensure a smooth and efficient registration journey for your API products. Our team of experts is well-versed in navigating Bangladesh’s regulatory framework, guaranteeing compliance with precision and timeliness. From documentation to approval, we provide personalized support every step of the way, ensuring your peace of mind and regulatory success. At Ziva DRA, we understand the importance of staying ahead in the dynamic pharmaceutical industry. That’s why we leverage industry-leading solutions and innovative strategies to deliver results that exceed expectations. Don’t let regulatory challenges hold you back! Partner with Ziva DRA today and unlock new opportunities in Bangladesh’s pharmaceutical market. Reach out to us now to kickstart your API registration process and take your business to new heights! #APIRegistration #BangladeshPharma #ZivaDRA #RegulatoryExcellence #InnovationInProgress

The pharmaceutical industry and key European organisations such as the EFPIA continue to express concerns about the Commission’s proposed OMP legislation changes. Key issues include uncertainties associated with the definition of unmet need and the feasibility of launching in all member states within 2 years of marketing authorisation. To find out more about these changes and how they might influence the rare disease landscape, follow the link to the blog post written by Iro Malekou and Srishti Gupta. 👉 Link: https://lnkd.in/e746pheU #P4A #P4Ainsights #eu #legislation #orphan #orphandrugs #rare #rarediseases #Eupharmaceuticallegislation

Unveiling Essential Insights: European Medicines Agency's Latest Highlights are out now! With European Medicines Agency (#EMA) in #EU, staying up-to-date on pharmaceutical news has never been more accessible. Keeping abreast of the latest pharmaceutical updates is pivotal for ensuring optimal patient care and safety. #pharma #healthcare #patientsafety #regulatoryaffairs PharmOut, we recognise the significance of proactive vigilance in pharmaceuticals and fostering a culture of continuous learning.

 OPPI, representing research-based global pharmaceutical companies in India, advocates for a stable and predictable drug pricing policy. They urge the government to avoid using Para 19 of the Drug Pricing Control Order (DPCO), which allows significant price reductions. Let’s prioritize patient access and innovation! 💊 #Healthcare #PharmaIndustry #DrugPricing”

🔗 Ziva DRA: Your Trusted Partner for API Registration in Bangladesh! 🔗 Ziva DRA now offers specialized Active Pharmaceutical Ingredients (API) registration services tailored for Bangladesh. With our deep expertise and streamlined processes, we ensure a smooth and efficient registration journey for your API products. Our team of experts is well-versed in navigating Bangladesh’s regulatory framework, guaranteeing compliance with precision and timeliness. From documentation to approval, we provide personalized support every step of the way, ensuring your peace of mind and regulatory success. At Ziva DRA, we understand the importance of staying ahead in the dynamic pharmaceutical industry. That’s why we leverage industry-leading solutions and innovative strategies to deliver results that exceed expectations. Don’t let regulatory challenges hold you back! Partner with Ziva DRA today and unlock new opportunities in Bangladesh’s pharmaceutical market. Reach out to us now to kickstart your API registration process and take your business to new heights! #APIRegistration #BangladeshPharma #ZivaDRA #RegulatoryExcellence #InnovationInProgress

🔗 Ziva DRA: Your Trusted Partner for API Registration in Bangladesh! 🔗 Ziva DRA now offers specialized Active Pharmaceutical Ingredients (API) registration services tailored for Bangladesh. With our deep expertise and streamlined processes, we ensure a smooth and efficient registration journey for your API products. Our team of experts is well-versed in navigating Bangladesh’s regulatory framework, guaranteeing compliance with precision and timeliness. From documentation to approval, we provide personalized support every step of the way, ensuring your peace of mind and regulatory success. At Ziva DRA, we understand the importance of staying ahead in the dynamic pharmaceutical industry. That’s why we leverage industry-leading solutions and innovative strategies to deliver results that exceed expectations. Don’t let regulatory challenges hold you back! Partner with Ziva DRA today and unlock new opportunities in Bangladesh’s pharmaceutical market. Reach out to us now to kickstart your API registration process and take your business to new heights! #APIRegistration #BangladeshPharma #ZivaDRA #RegulatoryExcellence #InnovationInProgress